OncoMatch/Clinical Trials/NCT06083844
Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy
Is NCT06083844 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Pembrolizumab and Bevacizumab for ovarian cancer.
Treatment: Pembrolizumab · Bevacizumab · Cyclophosphamide — To find out if combining pembrolizumab, bevacizumab (or an equivalent biosimilar drug), and low-dose cyclophosphamide can help control high-grade ovarian cancer that has MRD after treatment. The safety of this treatment combination will also be studied.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Chemotherapy
Cancer type
Ovarian Cancer
Biomarker criteria
Excluded: BRCA1 deleterious germline or somatic mutation
Excluded: BRCA2 deleterious germline or somatic mutation
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: platinum-based chemotherapy — frontline
Have received standard of care frontline surgical and chemotherapy treatment (at least six cycles of platinum and taxane (or equivalent, with or without bevacizumab/biosimilar therapy). Patients who received neoadjuvant therapy are included.
Must have received: taxane — frontline
at least six cycles of platinum and taxane (or equivalent, with or without bevacizumab/biosimilar therapy)
Cannot have received: anti-PD-1 therapy
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX 40, CD137).
Cannot have received: anti-PD-L1 therapy
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX 40, CD137).
Cannot have received: anti-PD-L2 therapy
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX 40, CD137).
Cannot have received: checkpoint inhibitor
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX 40, CD137).
Lab requirements
Blood counts
anc ≥ 1,000 /mcl; platelets ≥ 100,000 / mcl; hgb ≥8 g/dl (transfusion allowed)
Kidney function
creatinine clearance ≥30 ml/min (measured or calculated per local practice)
Liver function
total bilirubin ≤ 1.5 × uln or ≤ 3 × uln in the case of suspected/documented gilbert's syndrome; ast (sgot) and alt (sgpt) ≤ 2.5 x uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering Cancer Center · New York, New York
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06083844 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-PD-1 therapy, anti-PD-L1 therapy, anti-PD-L2 therapy disqualifies patients from enrollment.
Are patients with BRCA1 alterations eligible?
No. BRCA1 deleterious germline or somatic mutation is an exclusion criterion.
Are patients with BRCA2 alterations eligible?
No. BRCA2 deleterious germline or somatic mutation is an exclusion criterion.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages